TY - JOUR
T1 - Antithrombotic therapy in patients with acute coronary syndrome
T2 - similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines
AU - Landi, Antonio
AU - Aboyans, Victor
AU - Angiolillo, Dominick J
AU - Atar, Dan
AU - Capodanno, Davide
AU - Fox, Keith A A
AU - Halvorsen, Sigrun
AU - James, Stefan
AU - Jüni, Peter
AU - Leonardi, Sergio
AU - Mehran, Roxana
AU - Montalescot, Gilles
AU - Navarese, Eliano Pio
AU - Niebauer, Josef
AU - Oliva, Angelo
AU - Piccolo, Raffaele
AU - Price, Susanna
AU - Storey, Robert F
AU - Völler, Heinz
AU - Vranckx, Pascal
AU - Windecker, Stephan
AU - Valgimigli, Marco
N1 - Niebauer: University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
PY - 2024/2/9
Y1 - 2024/2/9
N2 - Antithrombotic therapy represents the cornerstone of the pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration of antithrombotic therapy is still matter of debate requiring a critical assessment of patient comorbidities, clinical presentation, revascularization modality, and/or optimization of medical treatment. The 2023 European Society of Cardiology (ESC) guidelines for the management of patients with ACS encompassing both patients with and without ST segment elevation ACS have been recently published. Shortly before, a European expert consensus task force produced guidance for clinicians on the management of antithrombotic therapy in patients with ACS as well as chronic coronary syndrome. The scope of this manuscript is to provide a critical appraisal of differences and similarities between the European consensus paper and the latest ESC recommendations on oral antithrombotic regimens in ACS patients.
AB - Antithrombotic therapy represents the cornerstone of the pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration of antithrombotic therapy is still matter of debate requiring a critical assessment of patient comorbidities, clinical presentation, revascularization modality, and/or optimization of medical treatment. The 2023 European Society of Cardiology (ESC) guidelines for the management of patients with ACS encompassing both patients with and without ST segment elevation ACS have been recently published. Shortly before, a European expert consensus task force produced guidance for clinicians on the management of antithrombotic therapy in patients with ACS as well as chronic coronary syndrome. The scope of this manuscript is to provide a critical appraisal of differences and similarities between the European consensus paper and the latest ESC recommendations on oral antithrombotic regimens in ACS patients.
KW - Humans
KW - Acute Coronary Syndrome/drug therapy
KW - Fibrinolytic Agents/therapeutic use
KW - Consensus
KW - Cardiology
KW - Antithrombotic therapy
KW - Antiplatelets
KW - Acute coronary syndrome
KW - Coronary artery disease
U2 - 10.1093/ehjacc/zuad158
DO - 10.1093/ehjacc/zuad158
M3 - Review article
C2 - 38170562
SN - 2048-8726
VL - 13
SP - 173
EP - 180
JO - EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
JF - EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
IS - 1
ER -